Latest Insider Transactions at Cvs Health Corp (CVS)
This section provides a real-time view of insider transactions for Cvs Health Corp (CVS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of CVS HEALTH Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of CVS HEALTH Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 07
2018
|
Anne A. Finucane Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,332
+50.0%
|
$103,896
$78.77 P/Share
|
|
Nov 07
2018
|
Jean Pierre Millon Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,332
+50.0%
|
$103,896
$78.77 P/Share
|
|
Nov 07
2018
|
Tony L White Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,332
+4.62%
|
$103,896
$78.77 P/Share
|
|
Oct 01
2018
|
Lisa Bisaccia Former EVP & Chief HR Officer |
SELL
Open market or private sale
|
Direct |
21,534
-33.21%
|
$1,722,720
$80.0 P/Share
|
|
Oct 01
2018
|
Lisa Bisaccia Former EVP & Chief HR Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,534
+24.76%
|
$1,055,166
$49.8 P/Share
|
|
Oct 01
2018
|
Eva C Boratto EVP & CFO |
SELL
Open market or private sale
|
Direct |
4,426
-9.56%
|
$354,080
$80.0 P/Share
|
|
Oct 01
2018
|
Eva C Boratto EVP & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,426
+8.73%
|
$239,004
$54.53 P/Share
|
|
Sep 17
2018
|
Eva C Boratto EVP & CFO |
SELL
Open market or private sale
|
Direct |
13,311
-24.13%
|
$1,024,947
$77.16 P/Share
|
|
Sep 17
2018
|
Eva C Boratto EVP & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
13,311
+19.44%
|
$598,995
$45.07 P/Share
|
|
Aug 27
2018
|
Kevin Hourican EVP & President, CVS Pharmacy |
SELL
Open market or private sale
|
Direct |
8,564
-70.57%
|
$642,300
$75.0 P/Share
|
|
Aug 27
2018
|
Kevin Hourican EVP & President, CVS Pharmacy |
BUY
Exercise of conversion of derivative security
|
Direct |
4,426
+26.73%
|
$239,004
$54.53 P/Share
|
|
Jun 04
2018
|
Tony L White Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,638
+5.89%
|
$104,832
$64.1 P/Share
|
|
Jun 04
2018
|
Richard M Bracken Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,725
+14.73%
|
$110,400
$64.1 P/Share
|
|
Jun 04
2018
|
Alecia A Decoudreaux Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,638
+50.0%
|
$104,832
$64.1 P/Share
|
|
Jun 04
2018
|
Nancy Ann Deparle Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,638
+12.91%
|
$104,832
$64.1 P/Share
|
|
Jun 04
2018
|
David W Dorman Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,446
+3.92%
|
$284,544
$64.1 P/Share
|
|
Jun 04
2018
|
Anne A. Finucane Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,638
+50.0%
|
$104,832
$64.1 P/Share
|
|
Jun 04
2018
|
Jean Pierre Millon Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,638
+50.0%
|
$104,832
$64.1 P/Share
|
|
May 04
2018
|
C David Brown Ii Director |
BUY
Open market or private purchase
|
Direct |
10,000
+8.99%
|
$610,000
$61.99 P/Share
|
|
May 04
2018
|
David W Dorman Director |
BUY
Open market or private purchase
|
Direct |
24,300
+18.85%
|
$1,506,600
$62.22 P/Share
|
|
Apr 01
2018
|
Larry J Merlo Director |
SELL
Payment of exercise price or tax liability
|
Direct |
25,498
-7.17%
|
$1,580,876
$62.21 P/Share
|
|
Apr 01
2018
|
David M Denton EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,351
-14.58%
|
$269,762
$62.21 P/Share
|
|
Apr 01
2018
|
Thomas M Moriarty EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
4,629
-14.45%
|
$286,998
$62.21 P/Share
|
|
Apr 01
2018
|
Lisa Bisaccia Former EVP & Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,162
-9.3%
|
$134,044
$62.21 P/Share
|
|
Apr 01
2018
|
Eva C Boratto EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
594
-1.4%
|
$36,828
$62.21 P/Share
|
|
Apr 01
2018
|
Troyen A Brennan EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,047
-4.56%
|
$250,914
$62.21 P/Share
|
|
Feb 28
2018
|
Thomas M Moriarty EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
4,650
+10.1%
|
$311,550
$67.73 P/Share
|
|
Feb 28
2018
|
Jonathan C Roberts EVP & Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,979
+3.54%
|
$400,593
$67.73 P/Share
|
|
Feb 28
2018
|
Larry J Merlo Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,616
+2.25%
|
$979,272
$67.73 P/Share
|
|
Feb 28
2018
|
David M Denton EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,613
-6.8%
|
$108,071
$67.73 P/Share
|
|
Feb 28
2018
|
David M Denton EVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
5,315
+18.31%
|
$356,105
$67.73 P/Share
|
|
Feb 28
2018
|
Troyen A Brennan EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,208
-1.49%
|
$80,936
$67.73 P/Share
|
|
Feb 28
2018
|
Troyen A Brennan EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,986
+4.69%
|
$267,062
$67.73 P/Share
|
|
Feb 28
2018
|
Lisa Bisaccia Former EVP & Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
885
-4.79%
|
$59,295
$67.73 P/Share
|
|
Feb 28
2018
|
Lisa Bisaccia Former EVP & Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,923
+13.66%
|
$195,841
$67.73 P/Share
|
|
Feb 28
2018
|
Eva C Boratto EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
517
-0.64%
|
$34,639
$67.73 P/Share
|
|
Feb 28
2018
|
Eva C Boratto EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
797
+1.92%
|
$53,399
$67.73 P/Share
|
|
Feb 27
2018
|
Eva C Boratto EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
197
-0.5%
|
$13,396
$68.25 P/Share
|
|
Feb 20
2018
|
David M Denton EVP and CFO |
SELL
Other acquisition or disposition
|
Direct |
18,057
-49.53%
|
-
|
|
Feb 20
2018
|
David M Denton EVP and CFO |
SELL
Other acquisition or disposition
|
Direct |
38,836
-25.4%
|
-
|
|
Feb 16
2018
|
Helena Foulkes EVP & President-CVS Pharmacy |
SELL
Open market or private sale
|
Direct |
19,965
-30.68%
|
$1,417,515
$71.04 P/Share
|
|
Feb 16
2018
|
Helena Foulkes EVP & President-CVS Pharmacy |
BUY
Exercise of conversion of derivative security
|
Direct |
19,965
+23.48%
|
$898,425
$45.07 P/Share
|
|
Dec 21
2017
|
Lisa Bisaccia Former EVP & Chief HR Officer |
SELL
Open market or private sale
|
Direct |
29,445
-65.43%
|
$2,208,375
$75.0 P/Share
|
|
Nov 08
2017
|
Richard M Bracken Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,630
+16.48%
|
$110,840
$68.99 P/Share
|
|
Nov 08
2017
|
Nancy Ann Deparle Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,521
+13.91%
|
$103,428
$68.99 P/Share
|
|
Nov 08
2017
|
David W Dorman Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,131
+4.89%
|
$280,908
$68.99 P/Share
|
|
Nov 08
2017
|
Jean Pierre Millon Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,521
+50.0%
|
$103,428
$68.99 P/Share
|
|
Nov 08
2017
|
Tony L White Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,521
+5.84%
|
$103,428
$68.99 P/Share
|
|
Oct 02
2017
|
Thomas M Moriarty EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
20,547
-47.59%
|
$1,664,307
$81.17 P/Share
|
|
Oct 02
2017
|
Thomas M Moriarty EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
20,547
+32.24%
|
-
|